Serina Therapeutics, Inc. Deposits Assets, Noncurrent
Serina Therapeutics, Inc. (SER) had Deposits Assets, Noncurrent of $50.00 thousand as of 2022-06-30, per its 10-Q filed 2022-08-12.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DepositsAssetsNoncurrent · last filed 2022-08-12
- 2022-06-30: Deposits Assets, Noncurrent $50.00K.
- 2022-03-31: Deposits Assets, Noncurrent $50.00K.
- 2021-12-31: Deposits Assets, Noncurrent $50.00K.
- 2021-09-30: Deposits Assets, Noncurrent $50.00K.
| Period end | Deposits Assets, Noncurrent |
|---|---|
| 2022-06-30 | $50.00K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $50.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $50.00K 10-Q · filed 2022-08-12 |
| 2021-09-30 | $50.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $50.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $50.00K 10-Q · filed 2021-05-17 |
| 2020-12-31 | $50.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $100.00K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $100.00K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $111.00K 10-Q · filed 2020-05-14 |
| 2019-12-31 | $111.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $193.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $196.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $19.00K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $19.00K 10-K/A · filed 2020-03-31 |
| 2017-12-31 | $35.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |